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Objective: This study investigates sulphated glycosaminoglycans (sGAG) content changes in early oste-
oarthritis (OA), and whether contrast-enhanced magnetic resonance imaging (MRI) of cartilage in vitro
may identify early event of OA pathology.
Method: Osteochondral plugs from patients with hip OA or femoral neck fracture (reference group) were
collected and analysed by 1.5 T MRI with DR1 as a measure of cartilage contrast concentration. Cartilage
hydration, contents of sGAG, cartilage oligomeric matrix protein (COMP), hydroxyproline, denatured
collagen, and aggrecan TEGE392 neoepitope were determined and histological grading was performed.
Results: sGAG content correlated to DR1, although no difference in either of these parameters was
detectable between OA and reference cartilage at 4 h of contrast equilibration. In contrast, biochemical
analysis of other cartilage matrix constituents showed distinct alterations typical for early cartilage
degradation in OA cartilage and with clear evidence for increased aggrecan turnover.
Conclusion: In the present in vitro study, cartilage sGAG content could not distinguish between early OA
cartilage and reference cartilage. Given, that delayed gadolinium enhanced MRI of cartilage (dGEMRIC)
indicates early events in the pathogenesis of OA in vivo, our results from the in vitro studies imply other,
additional factors than cartilage sGAG content, e.g., alterations in diffusion or increased supply of contrast
agent in the diseased joint. Alternatively, an altered dGEMRIC reﬂects later stages of OA, when sGAG
content decreases. Further investigations are warranted, to understand variations in sGAG content in
pathology, an essential background for interpreting dGEMRIC measurements.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Detection of early events in osteoarthritis (OA) is of major
interest in cartilage research. During developing cartilage damage,
the role of extracellular matrix molecules has been investigated1.
Sulphated glycosaminoglycans (sGAG), mainly situated on aggre-
can, has been considered to play a central role in cartilage
homeostasis, since its negative charge attracts water into cartilage,
creating a high osmotic pressure. This is counteracted by the tensile
strength of an intact collagen network2,3, which is arranged by
other cartilage matrix proteins such as cartilage oligomeric matrix
protein (COMP)4,5.J.J. Stubendorff, Joint and Soft
Lund University, Department
, SE-20502 Malmö, Sweden.
. Stubendorff).
s Research Society International. PIn pathology, the balance between synthesis and degradation of
cartilage matrix constituents is altered6. The aggrecan derived
393ARGS neoepitope (from aggrecanase cleavage at TEGE392-
Y393ARGS)7 has been proposed to reﬂect early pathology, seen as
elevating 393ARGS levels in the synovial ﬂuid of OA and knee
injured patients8,9. Increased serum COMP levels in patient groups
with joint disease have been related to a more rapid progress of
tissue destruction10,11.
Delayed gadolinium enhanced magnetic resonance imaging of
cartilage (dGEMRIC), introduced in 199612, is based on an inverse
relationship between the cartilage distribution of the negatively
charged contrast agent gadolinium-diethylene-triaminepentaacetic
acid (Gd-DTPA2) and the ﬁxed charged density, which is related to
sGAG content13. In vitro studies show that the contrast medium
distributes according to the GibbseDonnan equilibrium14. It has
been suggested that the same phenomenon is valid also in vivo15.
Early changes of OA are suggested to be accompanied withublished by Elsevier Ltd. All rights reserved.
J.J. Stubendorff et al. / Osteoarthritis and Cartilage 20 (2012) 396e404 397a decrease in cartilage sGAG content and a number of clinical studies
have been using dGEMRIC to study cartilage quality16e18.
However, the mechanism is not clear how early changes of OA
are accompanied by changes in cartilage sGAG content and there
are conﬂicting data suggesting elevated19e21, unchanged22e24 and
decreased25,26 sGAG contents.
Therefore, we aimed with this study, to investigate: (1) how
sGAG content reﬂects degradation in cartilage, (2) whether
dGEMRIC can conﬁrm changed sGAG in vitro, (3) and thereby
demonstrate early OA pathology in vitro.Materials and methods
Patients and cartilage samples
Femoral heads of patients with OA (n ¼ 8, median age ¼ 62
years, range: 51e68 years) and of patients with osteoporotic
femoral neck fracture (reference cartilage, REF, n ¼ 8, median
age ¼ 81.5 years, range: 78e89 years), due to low impact fall
trauma, were collected at surgery and frozen at 20C tightly
covered with Paraﬁlm until further analysis. The study has been
approved by the institutional review board.Preparation for contrast-enhanced MRI
Femoral heads were thawed and cartilage bone plugs with
a diameter of 6 mm were punched out. We harvested full
thickness cartilage from the superior, habituell loaded part of the
caput [Fig. 1(a)] with an intact surface as close as possible to
the sites of advanced destruction [i.e., OA, Fig. 1(b)] and at cor-
responding regions with no sign of macroscopic damages (i.e.,
REF).
The plugs were arranged in a box with eight chambers and
equilibrated in 15 ml phosphate buffered saline (PBS), pH 7.4 for 4 h
at room temperature. Since the subchondral bone was not sepa-
rated from the cartilage, the PBS medium had only access to the
cartilage via three surfaces. The box was then placed in a 1.5 T
system (Siemens Magnetom Sonata, Siemens Healthcare, Erlangen,
Germany) with a dedicated knee coil, in a manner to allow
measurement of eight samples at the same time (Fig. 2).Fig. 1. (a) Anterior-posterior X-ray of a hip joint. The rectangle illustrates the region of samp
of an OA caput femoris. Black asterisk: lack of cartilage due to OA. White asterisk: full thicContrast-enhanced MRI
For T1 measurement, a single-slice inversion recovery spin echo
sequence was used for both pre-contrast (TR ¼ 3000 ms,
TE ¼ 15 ms, six TI’s between 100 and 2800 ms, ETL ¼ 11,
matrix ¼ 256  256, FOV ¼ 143  143 mm, in-plane resolution
0.47mm, slice thickness¼ 3mm) and post-contrast (TR¼ 2000ms,
six TI’s between 50 and 1600 ms, other parameters unchanged)
time points. A single slice was localized to cover the central part of
all the samples. The scan times were 9 min, and 6 min for pre-
contrast and post-contrast T1 measurements, respectively. After
pre-contrast measurement, the samples were equilibrated in 1 mM
contrast agent solution Magnevist, (Bayer/Germany) or Omniscan
(GE Healthcare Oslo/Norway). Post-contrast T1 measurements were
performed immediately and 1, 2, 3 and 4 h after contrast agent
injection. In the ﬁrst setting including four OA and four REF
samples, we used two adjacent biopsy specimens for the different
contrast agents. In these samples, we measured T1 additionally
after 24 h of equilibration, which did not show differences
compared to 4 h of equilibration (data not shown). In the other
setting (also four of each samples), we used the identical sample for
ﬁrst the charged (i.e., Magnevist) and then the non-charged (i.e.,
Omniscan) contrast agent. In between the different sets of contrast,
we washed out the charged agent thoroughly by changing the
surrounding PBS 7 times over a time period of 24 h. T1 measure-
ments at 4 h after contrast agent administration did not show
differences, when the ﬁrst setting was compared to the second
setting.
T1 calculations and segmenting the regions of interest were
done using MATLAB (Mathworks Inc., Natick, MA) and MRI-
mapper (Massachusetts Institute of Technology and Beth Israel
Deaconess Medical Centre, Boston, MA, USA). Full-thickness region
of interest (ROI) was manually segmented into each cartilage piece
[Fig. 2(a/b)]. To avoid partial volume artefacts, the edges of the
samples were excluded in the radial direction.
To demonstrate the gadolinium (Gd) concentration in the
cartilage at different time points, the results for each sample are
shown as DR1 ¼ (1/T1Gd  1/T1pre), where T1Gd is the T1 value at
a certain time point after contrast agent injection and T1pre is the T1
value before Gd-DTPA2 injection. T1Gd usually depicts the dGEM-
RIC index in clinical in vivo studies.le harvesting in both OA and REF cartilages. (b) Representative cranial view photograph
kness sample as close as possible to degradation.
Fig. 2. (a and b): Representative ROI (red areas) illustrated on four REF (on the left) and four OA cartilage samples (on the right) at 4 h after addition of Magnevist. The specimens
were hold on the subchondral bone in plastic devices, “hanging” in the surrounding PBS medium (15 ml in every box) allowing the contrast agent penetrating from three sides into
the cartilage. The pins of the sample holding devices are attached at the centre of the sample clamp, and indicate that the samples are satisfactorily arranged in the same orientation
as the MRI scan is performed. (b) Segmentation of representative sample: the subchondral bone appears as a black stripe between the cartilage and the trabecular bone. To avoid
partial volume artefacts, the edges of the samples were excluded in the radial direction.
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After MRI measurements, the PBS media were saved and frozen
at 20C until further analysis. The cartilage pieces were cut from
the subchondral bone and divided in two pieces, one for extraction
and quantiﬁcation of extracellular matrix (ECM) molecules, and the
other for histology. For the samples aimed for protein quantiﬁca-
tion, we obtained the wet weight and dry weight, after freeze-
drying. The water content was calculated [((wet weight  dry
weight)/wet weight)  100]. The samples for histology were frozen
until further analyses.
Protein extraction
The cartilage samples were cut into small pieces and extracted
with 4 M GueHCl containing protease-inhibitor cocktail for 24 h at
4C as previously5. After centrifugation, the pellets were frozen
at 20C until further analysis. The supernatants were used to
quantify sGAG, COMP, and aggrecan TEGE fragments.
Protein quantiﬁcation in cartilage extracts
In OA and REF cartilage extracts, sGAG contents were quantiﬁed
by Alcian Blue measurements according to the manufacture (Wie-
slab, Lund)27. COMP was quantiﬁed with an inhibition ELISA using
human recombinant COMP as coat and an anti bovine COMP anti-
body28. The total amount of extracted protein was determined by
BRADFORD-assay29. All biochemical variables were related to tissue
wet weight, since we interpret cartilage water content as a func-
tional compartment.
Protein quantiﬁcation in PBS medium
In order to enrich the protein concentration, in the 15 ml PBS
medium (from MRI measure), two 3 ml aliquots were precipitated
twice with 10 volumes of 96% ethanol, containing 50 mM NaAc at
4C over night. The precipitates were recovered by centrifugation
and either dissolved in 100 ml COMP-ELISA buffer (PBS, pH 7.4,
containing 0.8% SDS)28 or dissolved in 100 ml 4 M GueHCl for sGAG
quantiﬁcation.
Quantiﬁcation of TEGE392
GueHCl extracts were prepared and used for the quantiﬁcation
of aggrecanase generated aggrecan neoepitope TEGE392. Samples
were deglycosylated and prepared as described30,31, and applied on4e12% BiseTris SDS-PAGE mini gels (Invitrogen). An anti-NITEGE
antibody (i.e., sera32) was used to detect the aggrecan neoepitope
TEGE392 and to quantify its relative abundance by Western blot
using a luminescence image analyzer (Fujiﬁlm LAS 1000)30.
Aggrecan amino acid numbers in this paper are based on full
length human sequences starting with the N-terminal 1MTTL (NCBI
accession nr P16112).
Collagen analysis
The residual pellets after GuanidineeHCl extraction were used
to determine collagen content by measurement of hydroxyproline
by the StegmanneStalder colourimetric procedure33. The
percentage of extractable collagen (i.e., denatured collagen) was
analysed as described34.
Histology
Corresponding cartilage pieces were thawed and embedded in
Parafﬁn. Sections were cut (7 mm), stained with Safranin-O and Fast
Green35 and graded according to Mankin36 independently by three
investigators. Mean values are presented.
Statistical procedures
Statistical calculations were performed with SPSS 17.0 for
Windows. Group differences were determined by ManneWhitney
U test for group comparisons. To test for relationships between
parameters, Spearman’s rank (rs) correlation tests were performed.
One sample of the OA group (sample #48) has been excluded from
statistical analyses (see Results).
Reproducibility/reliability
For biochemical variables (sGAG, COMP, TEGE, hydroxyproline,
denatured collagen), established methods have been described
elsewhere27e31,33,34. For each variable, samples were analysed in
duplicates, and the means were used for further evaluations.
MRI measurements: the measurement chamber was never
removed from the coil between the T1 measurements. Therefore,
the ROIs could be copied from the ﬁrst time point to all the other
time points, and the possible error due to sample repositioning was
eliminated. The differentiating of cartilage from the surrounding
materials (PBS or Gd solution on three sides, subchondral bone on
one side) was easy. Even though the specimens were quite small
and the resolution was low, we are conﬁdent, that the ROIs
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shown to have good reproducibility, provided the same ROI is
chosen37. The current setupmimicks the in vivomeasurements, and
because the repositioning error is eliminated, the reproducibility of
this setup can be considered to be equal or better than that of
in vivo setup.Results
Contrast-enhanced MRI
The distribution of Magnevist into OA and REF cartilage was
fastest directly after the addition of the contrast agent and reached
equilibrium after 3e4 h (Fig. 3). DR1 at 4 h did not show differences
between OA and REF cartilages (P ¼ 0.798).
The non-charged contrast agent Omniscan entered the cartilage
at a higher rate compared to the charged Magnevist (Fig. 3). As for
Magnevist there were no differences in DR1 between OA and REF
cartilage at 4 h (P ¼ 0.721). However, DR1 at 4 h in the non-charged
Omniscan samples were higher compared to the charged Mag-
nevist (P < 0.001, Fig. 3), indicating that more contrast agent had
entered the cartilage.Biochemical analyses of cartilage
OA samples had signiﬁcant higher water contents than REF
samples [median OA 74.0%, REF 66.9%, P ¼ 0.006, Fig. 4(a)].
There were no differences in sGAG concentrations and amount
of extractable proteins between OA and REF samples [Fig. 4(b), data
not shown]. In contrast, COMP concentration was higher in
OA- compared to REF-cartilage [P ¼ 0.006, Fig. 4(c)]. One sample of
the OA group (sample #48) contained almost no detectable sGAG
and COMP, but released 98% of sGAG and 64% of COMP into the PBS
medium during equilibration. It differed histologically from the
others, by having deep cleavages in the matrix, no staining for
proteoglycans in the deep layer and irregular staining for the
collagen network [Fig. 5(d)], most likely representing much more
advanced stages of OA. Therefore, sample #48 was excluded from
the statistical data presented. The other cartilage samples showed
a low release (sGAG release in OA samples 1.28% of the total sGAGFig. 3. Dynamics of the uptake of Magnevist and Omniscan. Mean-DR1 after addition
of 1 mM contrast agent. Boxes indicate the use of Omniscan, circles the use of Mag-
nevist. White symbols indicate REF cartilage (n ¼ 8), black symbols indicate OA
cartilage (n ¼ 7). The arrow indicates the time point for addition of contrast agent.
Error bars ¼ 95% conﬁdence interval.content vs REF samples 0.44%, P¼ 0.014; COMP in OA samples 1.19%
vs REF samples 0.96%, not signiﬁcant).
The TEGE392 epitope concentration, reﬂecting aggrecan frag-
mentation, was variable in the OA cartilage and was not different
from the REF samples [P ¼ 0.152, Fig. 4(d)].
The cartilage hydroxyproline content was lower in OA (9.44 mg/
mgww) than in REF samples (11.79 mg/mgww) [P< 0.001, Fig. 4(e)]
and in accordance the relative amount of denatured collagen was
higher in OA than REF samples [9.39% vs 2.32%, P ¼ 0.009, Fig. 4(f)].
Correlation analyses
We chose the hydration of the cartilage as a general indicator of
cartilage quality25,38. The water content was negatively correlated
with the collagen content (r ¼ 0.843, P < 0.001) and positively
correlated with the fraction of denatured collagen (r ¼ 0.512,
P ¼ 0.043).
The relative abundance of the TEGE392 epitope correlated to the
water content (r ¼ 0.754, P ¼ 0.001), and also negatively to the
hydroxyproline content (r ¼ 0.638, P ¼ 0.008). There was no
correlation between cartilage sGAG or COMP concentration and
water content [Fig. 5(a, b)].
sGAG content and histology
Histological grading according to Mankin36 revealed that the OA
samples (excluding sample #48) weremore destroyed than the REF
samples (median Mankin score 3.25 vs 1.25, P < 0.001). OA and REF
sample pairs with similar sGAG and water contents (i.e., OA #41 e
REF #38 and OA #47 e REF #45), and OA and REF pairs with similar
sGAG- but different water contents (i.e., OA #36 e REF #44 and OA
#35 e REF #39) were compared histologically [Fig. 5(c)]. Cell
hypertrophy, hypercellularity and rough surfaces in the OA samples
indicated degradation, even though the sGAG content was similar
compared to REF cartilage [Fig. 5(a, c)].
sGAG content and dGEMRIC
After 4 h incubation with Magnevist the DR1 correlated to the
sGAG content (r ¼ 0.618, P ¼ 0.014, Fig. 6), whereas incubation
with Omniscan did not (r ¼ 0.246, P ¼ 0.376).
Discussion
In the present study, we characterised and compared OA hip
cartilage with osteoporotic femoral neck fracture cartilage (refer-
ence) with the hypothesis that sGAG content in OA cartilage is
decreased, reﬂecting early degradation2,25,26,39,40. We quantiﬁed
sGAG with biochemical (Alcian Blue) and contrast-enhanced MRI
(dGEMRIC) methods, prior to the analysis of cartilage composition
with different biochemical tools. Although the number of samples
was low, we observed signiﬁcant differences in most of the
biochemical parameters indicating different grades of cartilage
destruction. As a notable exception, we were not able to detect
differences in cartilage sGAG content.
Grushko et al. 25 showed that the sGAG content in normal hip
cartilage is quite homogenous in the superior, anterior and poste-
rior part of the femoral head, and the variation in sGAG and water
content for patients in the corresponding age to the presently
studied OA (62 years) and REF patients (81 years) are not
pronounced. When diseased, signiﬁcant increase of water content
in age- and site-matched OA samples (hip fracture 70% up to OA
75%) has been reported25. In analogy, we suggest that differences in
water content here observed (ca. 67% in REF cartilage vs 74% in OA)
are not due to differences in age or localisation, but are related to
Fig. 4. Comparison of biochemical parameters (a: water, b: sGAG, c: COMP, d: TEGE, e: hydroxyproline, f: denatured collagen) between OA (n ¼ 7) and REF (n ¼ 8) cartilage.
Black circles indicate OA cartilage, white circles indicate REF cartilage, and the line indicates the median. Individual circles represent mean values of duplicate measurements.
* ¼ Statistical signiﬁcance (P < 0.05).
Fig. 5. (a) Relationship between water content and sGAG content. The numbers indicate samples which are compared histologically (in c). (b) Relationship between cartilage COMP
content and water content. (c) Histological comparison of OA and REF cartilage with Safranin-O/Fast Green stained histological sections. The numbers correspond to the samples,
chosen in Fig. 5a/b and the line corresponds to 100 pixels in the photo image, providing similar magniﬁcation in all sections (50). (d) Sample #48, which released the protein
content into PBS medium.
J.J. Stubendorff et al. / Osteoarthritis and Cartilage 20 (2012) 396e404400
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a function of an impaired strength of the collagen network, which
allows an increased water inﬂow and cartilage oedema2,3.
For interpretation of dGEMRIC, sGAG content is of major interest
in opposite to actual sGAG synthesis. Fibrillation of cartilage and
occurrence of hypertrophic chondrocytes seem to be of importance,
when monitoring sGAG content. Many studies report on a sGAG-
decrease in ﬁbrillated cartilage25,26,39,40, whereas other studies
report on a sGAG elevation in cartilage with hypertrophic
chondrocytes19,21.
In the present study, we had cartilage samples with visually
intact surfacewithoutﬁbrillation (not including sample#48),which
we consider being at early stages of degradation. The histology of
two OA samples with normal hydration (meaning similar hydration
compared to REF cartilage) and intact surface showed the occur-
rence of hypertrophic chondrocytes, possibly reﬂecting increased
turnover of the ECM proteins [e.g., Fig. 5(c), samples #41 and #47],
indicated also by an increased COMP content [Fig. 5(b)]20. In
contrast, OA samples with increased hydration, showed histological
irregularities of the surface, no hypertrophic chondrocytes and
decreasing COMP contents [Fig. 5(b)], probably reﬂecting stages
before ﬁbrillation and failing repair capacity [e.g., Fig. 5(c) sample
#35 and #36]. In the highly ﬁbrillated sample #48, we observed
pronounced release of ECM molecules into the surrounding bath
which may lead to underestimation of the actual cartilage sGAG
content, at least in the experimental setting. Even thenon-ﬁbrillated
OA samples released about three times more sGAG compared to the
REF samples, though at low level, which does probably not signiﬁ-
cantly inﬂuence the sGAG cartilage content. In accordance to other
studies, reporting elevated or no changes in sGAG content, we
interpret our results as compensatory synthesis secondary to an
increased release of sGAG from the ECM. In support it has been
shown that the sGAG turnover is fast24,41,42, indicating capacity of
chondrocytes to counteract degenerative processes.
The data presented are in agreement with our previous data on
early changes in knee OA showing no or minimal changes in the
sGAG content, but major alterations in the content of extracellular
matrix proteins20.Fig. 6. Relationship between sGAG and DR1 after 4 h incubation with the contrast
medium Magnevist.In accordance to earlier studies3,43 we found a relationship
between increased hydration and increased amount of denatured
collagen, reﬂected by the pool of collagen/hydroxyproline extract-
able with chymotrypsin34. We also found that the amount of total
hydroxyproline was decreased in the OA cartilage and correlated to
the water content. We conclude that in later stages of OA, indicated
by increasing hydration, collagen ﬁbres and molecules decorating
the collagen ﬁbril surface might become damaged by early degra-
dative processes in combination with osmotic and biomechanic
stress. The consequence is a looser collagen network and increase
in hydration. Damaged collagen will be proteolysed and may be
released out of the cartilage, which would explain the decrease of
the total hydroxyproline. Another explanation is cartilage oedema
with no compensatory increased collagen production.
Aggrecanases, key enzymes in early events of cartilage degra-
dation, cleave aggrecan at TEGE392Y393ARGS7,44e46. In OA the C-
terminal aggrecan neoepitope TEGE392 at least initially remains in
the ECM as a G1-TEGE fragment where the G1-domain is bound to
hyaluronic acid via the link protein. We interpreted an increased
abundance of TEGE392 as the accumulation of end products of
degenerative turnover due to increased activity of aggrecanases in
OA [Fig. 4(d)], reﬂecting cartilage degradation. Signiﬁcant correla-
tion between the abundance of TEGE392 and the water content and
hydroxyproline content supports this hypothesis.
We found a signiﬁcant increase in COMP content in the OA
samples [Fig. 4(c)], reﬂecting changes in the cartilage turnover.
According to its attributed role in collagen ﬁbre organisation4, its
increased levels in serum samples of RA and OA patients10,11, and in
analogy to ﬁndings by Lorenzo et al.20, we interpreted the increased
COMP contents in our studies as increased synthesis secondary to
repair attempts of the cartilage to degeneration.
The lower uptake of Magnevist compared to Omniscan (Fig. 3)
was interpreted as depending on the charge. In agreement to Bashir
et al.12,15 we found a correlation between cartilage sGAG content
and DR1-Magnevist (Fig. 6), and no correlation to DR1-Omniscan,
supporting the principles of dGEMRIC. We found, however, in
accordance with our biochemical results, no differences in DR1
between OA and REF cartilage (Fig. 3). In this respect, we were not
able to conﬁrm clinical dGEMRIC studies with intravenous injec-
tions of the contrast agent, which suggest a relationship between
alterations of T1/DR1 and the future development of OA16e18.
The GibbseDonnan equilibrium postulates equilibrium,
requiring a steady state of inﬂux and elimination. In contrast to
in vitro studies, the human body is not a closed systems, since fast
renal elimination and inﬂux into different body compartments
occur at the same time (e.g., fatfree-tissue47, joint capsle and
cartilage may be with different properties of contrast agent distri-
bution48). Thus it might be difﬁcult, to apply the GibbseDonnan
equilibrium in vivo correctly and differences in dGEMRIC between
diseased and healthy cartilage may therefore also be explained by
other factors.
We suggest diffusion as one possible factor, which is dependent
(1) on the supply of i.e., contrast agent, which might be
increased in diseased joints by increased circulation due to
inﬂammation, and (2) on composition of the cartilage matrix
(water content, integrity of collagen network), which, when
diseased, may allow a faster contrast agent distribution49.
Presumed, the Donnan-theory is applicable in vivo and dGEM-
RIC is dependent on cartilage sGAG content only, our results would
indicate, that dGEMRIC depicts individuals with later stages of OA,
when cartilage is probably ﬁbrillated already, accompanied by
increased sGAG release and failing compensative sGAG synthesis.
Changes of dGEMRIC index have also been related to level of
physical activity in asymptomatic “healthy” volunteers, where the
contribution of diffusion is unclear, but might be more important
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cartilage sGAG content, which may alter diffusion. However,
present in vitro results showed differences between the uptake of
charged and non-charged contrast agent, indicating that the charge
(of cartilage and contrast agent) does play a role. This implies, that
differences of dGEMRIC in vivo may not be explained only by
diffusion either. Using contrast enhanced MRI and comparing
charged and non charged contrast agent in vivo may elucidate at
what stage in OA cartilage sGAG content resp diffusion inﬂuence
the dGEMRIC- index. In this respect, comparison can also be made
between OA and healthy cartilage.
Study limitations: (1) As described above, differences in age
between OA and REF group might affect the results, although our
belief is that the differences seen between OA and REF groups can
not be explained entirely by the differences in age, since Grushko
et al. showed, that the sGAG content in normal hip cartilage for
patients in the corresponding age to the presently studied OA and
REF patients are not pronounced25. (2) In the present study we
investigated only eight samples/individuals in each group. For most
of the variables the differences between groups were large enough
for statistical signiﬁcance, although a larger sample size might
change the non-signiﬁcant data. (3) The resolution of contrast-
enhanced MRI at 1.5 T is low, and small changes of DR1 after 4 h
might not be detected. Although, we chose 1.5 T MRI, to keep the
condition as similar as possible to the clinical dGEMRIC (1.5 T), since
differences in relaxation times in cartilage have been reported,
depending on ﬁeld strength50. (4) We can not take into account
possible spatial differences in sGAG concentration, since we ana-
lysed bulk cartilage only.
Summarised, we report similar sGAG level in cartilage samples
from hip OA patients and patients with femoral neck fracture
(reference samples), even though a number of biochemical
parameters indicated pronounced differences typical for changes in
early OA. sGAG content probably remains quite constant in early OA
secondary to compensative sGAG synthesis.
We conclude that the measurement of cartilage sGAG content,
measured in vitro by Alcian Blue precipitation or contrast-enhanced
MRI is not a sensitive/speciﬁc method to detect early cartilage
degeneration. In contrast, cartilage water content and COMP
content distinguish early OA from histological non-arthritic refer-
ence cartilage. Given, that dGEMRIC indicates early events in the
pathogenesis of OA in vivo, our results from the in vitro studies
imply that in addition to cartilage sGAG content, other factors may
also play a role, such as alterations in diffusion or increased supply
of contrast agent in the diseased joint. Alternatively, dGEMRIC
reﬂects later stages of OA, when sGAG content decreases. Further
investigations need to be done to relate to, and understand the
variations in sGAG content and other factors by pathology, which is
mandatory for interpreting in vivo dGEMRIC measurements.
Combination of biomarkers and cartilage imaging might aid in
better understanding of early events in the development of OA.Role of the funding source
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